Cristina Salvadori Bittar

Cristina Salvadori Bittar

Auto-generated profile, based on publicly available information

Cristina Salvadori Bittar

Faculdade de Medicina da Universidade de São Paulo

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2020 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
ICIsabela Bispo Santos da Silva Costa
Isabela Bispo Santos da Silva Costa
CBCristina Salvadori Bittar
Cristina Salvadori Bittar
SRStephanie Itala Rizk
Stephanie Itala Rizk
AAAntônio Everaldo de Araújo
Antônio Everaldo de Araújo
KSKaren Alcântara Queiroz Santos
Karen Alcântara Queiroz Santos
LHLudhmila Abrahão Hajjar
Ludhmila Abrahão Hajjar
In face of the pandemic of the novel coronavirus disease 2019 (COVID-19), the management of patients with cardiovascular risk factors and/or disease is challenging. The cardiovascular complications evidenced in patients with COVID-19 derive from several mechanisms, ranging from direct viral injury to complications secondary to the inflammatory and thrombotic responses to the infection. The proper care of patients with COVID-19 requires special attention to the cardiovascular system aimed at better outcomes.

18 November 2020 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
LHLudhmila Abrahão Hajjar
Ludhmila Abrahão Hajjar
ICIsabela Bispo Santos da Silva da Costa
Isabela Bispo Santos da Silva da Costa
MLMarcelo Antônio Cartaxo Queiroga Lopes
Marcelo Antônio Cartaxo Queiroga Lopes
PHPaulo Marcelo Gehm Hoff
Paulo Marcelo Gehm Hoff
MEMaria Del Pilar Estevez-Diz
Maria Del Pilar Estevez-Diz
RKRoberto Kalil
Roberto Kalil
1. Introdução Atualmente, doenças cardiovasculares (DCV) e câncer são as principais causas de mortalidade em todo o mundo e no Brasil.– As transições demográfica e epidemiológica ocorridas recentemente no nosso país resultaram no aumento da expectativa de vida da população, hoje em torno de 76 anos, e na modificação no perfil de saúde, em que doenças crônicas e suas complicações são prevalentes. Esses fatores ocasionam importantes desafios e a necessidade de uma agenda para as políticas de saúde que possam [...] 1. Introdução Atualmente, doenças cardiovasculares (DCV) e câncer são as principais causas de mortalidade em todo o mundo e no Brasil.– As transições demográfica e epidemiológica ocorridas recentemente no nosso país resultaram no aumento da expectativa de vida da população, hoje em torno de 76 anos, e na modificação no perfil de saúde, em que doenças crônicas e suas complicações são prevalentes. Esses fatores ocasionam importantes desafios e a necessidade de uma agenda para as políticas de saúde que possam

15 October 2020 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
LKLucas Tokio Kawahara
Lucas Tokio Kawahara
ICIsabela Bispo Santos da Silva Costa
Isabela Bispo Santos da Silva Costa
CBCecília Chie Sakaguchi Barros
Cecília Chie Sakaguchi Barros
GAGabriel Coelho de Almeida
Gabriel Coelho de Almeida
CBCristina Salvadori Bittar
Cristina Salvadori Bittar
PHPaulo M. Hoff
Paulo M. Hoff
Resumo O desafio imposto ao sistema de saúde pela pandemia da COVID-19 faz com que haja uma necessidade de readequações de rotinas e serviços de saúde, com os objetivos de controlar a disseminação do vírus e preservar a saúde. Torna-se ainda mais importante o manejo seguro e correto dos pacientes dos grupos de risco, como os pacientes idosos, os portadores de doenças cardiovasculares e os pacientes com câncer. Dessa forma, a cardio-oncologia ganha novo dimensionamento, no intuito de se adequar [...] Resumo O desafio imposto ao sistema de saúde pela pandemia da COVID-19 faz com que haja uma necessidade de readequações de rotinas e serviços de saúde, com os objetivos de controlar a disseminação do vírus e preservar a saúde. Torna-se ainda mais importante o manejo seguro e correto dos pacientes dos grupos de risco, como os pacientes idosos, os portadores de doenças cardiovasculares e os pacientes com câncer. Dessa forma, a cardio-oncologia ganha novo dimensionamento, no intuito de se adequar

1 November 2023 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
ARAmanda G. Rodrigues
Amanda G. Rodrigues
ASAllan R. K. Sales
Allan R. K. Sales
DFDiego Faria
Diego Faria
SFSilvia M. R. Fonseca
Silvia M. R. Fonseca
MBMarina M. K. Bond
Marina M. K. Bond
RFRoberto Kalil Filho
Roberto Kalil Filho
Patients with heart failure with reduced ejection fraction related to anthracycline-based chemotherapy have increased sympathetic nerve activity and decreased exercise capacity. These alterations in autonomic control and physical capacity are similar to those observed in patients with heart failure due to other etiologies. These findings highlight the importance of special care of oncological patients treated with chemotherapy.

20 May 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
SRStephanie Itala Rizk
Stephanie Itala Rizk
ICIsabela Bispo Santos da Silva Costa
Isabela Bispo Santos da Silva Costa
CCCecília Beatriz Bittencourt Viana Cruz
Cecília Beatriz Bittencourt Viana Cruz
BPBrunna Pileggi
Brunna Pileggi
FAFernanda Thereza de Almeida Andrade
Fernanda Thereza de Almeida Andrade
LHLudhmila Abrahão Hajjar
Ludhmila Abrahão Hajjar
Background: Cancer therapy–related cardiac dysfunction frequently occurs in patients receiving anthracycline. Ivabradine reduces heart rate without affecting contractility and showed anti‐inflammatory, antioxidant, and antiapoptotic effects in experimental cardiotoxicity models. This study aims to evaluate the effect of ivabradine on cancer therapy–related cardiac dysfunction in patients with lymphoma or sarcoma treated with anthracycline. Methods: In a randomized, triple‐blind trial, patients starting anthracycline therapy received either ivabradine 5 mg twice daily or placebo until 30 days after completing treatment. The primary outcome was the incidence of cardiotoxicity measured as a ≥10% relative reduction in global longitudinal strain at 12 months from baseline. Secondary outcomes included 12‐month clinical outcomes, a ≥10% decrease in the left ventricular ejection fraction to <55%, diastolic dysfunction, and troponin T and N‐terminal pro‐B‐type natriuretic peptide levels. Results: This study enrolled 107 patients (51 in the ivabradine group and 56 in the placebo group). The median dose of anthracycline was 300 mg/m 2 (250–300 mg/m 2 ) in both groups. Cardiotoxicity measured as a ≥10% relative reduction in global longitudinal strain at 12 months was reached in 57% versus 50% in the ivabradine and placebo groups (odds ratio, 1.32 [95% CI, 0.61–2.83]; P =0.477). Fewer patients in the ivabradine group than in the placebo group had troponin T levels ≥14 ng/L (16 [39.0%] versus 23 [62.2%]; P =0.041) at 6 months, with this difference not maintained at the 12‐month follow‐up. In addition, there were no differences in the other secondary outcomes. Conclusions: A fixed 10 mg/day dose of ivabradine does not protect patients with cancer against anthracycline cardiotoxicity. Registration: URL: https://clinicaltrials.gov/ ; Unique Identifier: NCT03650205.

1 October 2021 in IJC Heart & Vasculature
Verified
Journal Article
Open access
PGPatrícia O. Guimarães
Patrícia O. Guimarães
FSFrancis R. de Souza
Francis R. de Souza
RLRenato D. Lopes
Renato D. Lopes
CBCristina Bittar
Cristina Bittar
FCFrancisco A. Cardozo
Francisco A. Cardozo
RFRoberto Kalil Filho
Roberto Kalil Filho
Patients with Coronavirus Disease 2019 (COVID-19) may present high risk features during hospitalization, including cardiovascular manifestations. However, less is known about the factors that may further increase the risk of death in these patients. We included patients with COVID-19 and high risk features according to clinical and/or laboratory criteria at 21 sites in Brazil from June 10th to October 23rd of 2020. All variables were collected until hospital discharge or in-hospital death. A total of 2546 participants were included (mean age 65 years; 60.3% male). Overall, 70.8% were admitted to intensive care units and 54.2% had elevated troponin levels. In-hospital mortality was 41.7%. An interaction among sex, age and mortality was found (p = 0.007). Younger women presented higher rates of death than men (30.0% vs 22.9%), while older men presented higher rates of death than women (57.6% vs 49.2%). The strongest factors associated with in-hospital mortality were need for mechanical ventilation (odds ratio [OR] 8.2, 95% confidence interval [CI] 5.4–12.7), elevated C-reactive protein (OR 2.3, 95% CI 1.7–2.9), cancer (OR 1.8, 95 %CI 1.2–2.9), and elevated troponin levels (OR 1.8, 95% CI 1.4–2.3). A risk score was developed for risk assessment of in-hospital mortality. This cohort showed that patients with COVID-19 and high risk features have an elevated rate of in-hospital mortality with differences according to age and sex. These results highlight unique aspects of this population and might help identifying patients who may benefit from more careful initial surveillance and potential subsequent interventional therapies.